{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:12Z","timestamp":1790916972946,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01247-8","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:38:24Z","timestamp":1786682304000},"page":"721-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Claudin-18.2 in Gastric and Gastroesophageal Junction Adenocarcinoma: From Biology to Therapeutic Targeting: A Narrative Review"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2197-6426","authenticated-orcid":false,"given":"Robin","family":"Grellet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Facy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1247_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1247_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"1247_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1247_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"1247_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2000","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2000;391:1023\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3.","journal-title":"Lancet"},{"key":"1247_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"1247_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"1247_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1152\/physrev.00019.2012","volume":"93","author":"D G\u00fcnzel","year":"2013","unstructured":"G\u00fcnzel D, Yu ASL. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93:525\u201369. https:\/\/doi.org\/10.1152\/physrev.00019.2012.","journal-title":"Physiol Rev"},{"key":"1247_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.febslet.2011.01.028","volume":"585","author":"K Mineta","year":"2011","unstructured":"Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, et al. Predicted expansion of the Claudin multigene family. FEBS Lett. 2011;585:606\u201312. https:\/\/doi.org\/10.1016\/j.febslet.2011.01.028.","journal-title":"FEBS Lett"},{"key":"1247_CR10","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"key":"1247_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030679","volume":"16","author":"MC Mathias-Machado","year":"2024","unstructured":"Mathias-Machado MC, de Jesus VHF, J\u00e1come A, Donadio MD, Aruquipa MPS, Fogacci J, et al. Claudin 18.2 as a new biomarker in gastric cancer: what should we know? Cancers. 2024;16:679. https:\/\/doi.org\/10.3390\/cancers16030679.","journal-title":"Cancers"},{"key":"1247_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells14161285","volume":"14","author":"A Poniewierska-Baran","year":"2025","unstructured":"Poniewierska-Baran A, Plewa P, \u017babicka Z, Pawlik A. Claudin18.2 as a promising therapeutic target in gastric cancer. Cells. 2025;14:1285. https:\/\/doi.org\/10.3390\/cells14161285.","journal-title":"Cells"},{"key":"1247_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"key":"1247_CR14","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1242\/jcs.00389","volume":"116","author":"J Ikenouchi","year":"2003","unstructured":"Ikenouchi J, Matsuda M, Furuse M, Tsukita S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of Claudins\/occludin by Snail. J Cell Sci. 2003;116:1959\u201367. https:\/\/doi.org\/10.1242\/jcs.00389.","journal-title":"J Cell Sci"},{"key":"1247_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01406-8","volume":"22","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang Z, Jiang L, Zhang M, Zhang C, Shen L. Claudin-18.2 mediated interaction of gastric cancer cells and cancer-associated fibroblasts drives tumor progression. Cell Commun Signal. 2024;22:27. https:\/\/doi.org\/10.1186\/s12964-023-01406-8.","journal-title":"Cell Commun Signal"},{"key":"1247_CR16","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-21-4370","volume":"82","author":"RDZ Mullins","year":"2022","unstructured":"Mullins RDZ, Pal A, Barrett TF, Heft Neal ME, Puram SV. Epithelial-mesenchymal plasticity in tumor immune evasion. Cancer Res. 2022;82:2329\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4370.","journal-title":"Cancer Res"},{"key":"1247_CR17","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","volume":"27","author":"M Taki","year":"2021","unstructured":"Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, et al. Tumor immune microenvironment during epithelial-mesenchymal transition. Clin Cancer Res. 2021;27:4669\u201379. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4459.","journal-title":"Clin Cancer Res"},{"key":"1247_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of Claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8:100762. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762.","journal-title":"ESMO Open"},{"key":"1247_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100778","volume":"8","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Janjigian YY, Wainberg ZA. Claudin18.who? Examining biomarker overlap and outcomes in Claudin18.2-positive gastroesophageal adenocarcinomas. ESMO Open. 2023;8:100778. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100778.","journal-title":"ESMO Open"},{"key":"1247_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-186","volume":"6","author":"KJ Hewitt","year":"2006","unstructured":"Hewitt KJ, Agarwal R, Morin PJ. The Claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186. https:\/\/doi.org\/10.1186\/1471-2407-6-186.","journal-title":"BMC Cancer"},{"key":"1247_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1369\/0022155413479123","volume":"61","author":"\u00c1 Holczbauer","year":"2013","unstructured":"Holczbauer \u00c1, Gy\u00f6ngy\u00f6si B, Lotz G, Szij\u00e1rt\u00f3 A, Kupcsulik P, Schaff Z, et al. Distinct Claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas. J Histochem Cytochem. 2013;61:294\u2013305. https:\/\/doi.org\/10.1369\/0022155413479123.","journal-title":"J Histochem Cytochem"},{"key":"1247_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1596460","volume":"15","author":"W Ji","year":"2025","unstructured":"Ji W, Zhuang X, Jiang WG, Martin TA. Tight junctional protein family, Claudins in cancer and cancer metastasis. Front Oncol. 2025;15:1596460. https:\/\/doi.org\/10.3389\/fonc.2025.1596460.","journal-title":"Front Oncol"},{"key":"1247_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the Claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208:633\u201342. https:\/\/doi.org\/10.1002\/path.1922.","journal-title":"J Pathol"},{"key":"1247_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5230\/jgc.2026.26.e10","volume":"26","author":"F Zhang","year":"2026","unstructured":"Zhang F, Okazaki U, Nakayama I, Shitara K. CLDN18.2 in gastric cancer: current therapeutic landscape and future perspectives. J Gastric Cancer. 2026;26:127\u201345. https:\/\/doi.org\/10.5230\/jgc.2026.26.e10.","journal-title":"J Gastric Cancer"},{"key":"1247_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100844","volume":"38","author":"SP Stratton","year":"2025","unstructured":"Stratton SP, Pang L, Pugh J, Kouzova M, Baldwin D, McDonald J, et al. Analytical and clinical performance of the VENTANA CLDN18 (43-14A) RxDx assay in gastric and gastroesophageal junction adenocarcinoma tissue samples in SPOTLIGHT and GLOW. Mod Pathol. 2025;38:100844. https:\/\/doi.org\/10.1016\/j.modpat.2025.100844.","journal-title":"Mod Pathol"},{"key":"1247_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu R-H, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27:1058\u201368. https:\/\/doi.org\/10.1007\/s10120-024-01518-1.","journal-title":"Gastric Cancer"},{"key":"1247_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101233","volume":"4","author":"S Derks","year":"2023","unstructured":"Derks S, van Laarhoven HWM. SPOTlight on GLOW. Cell Rep Med. 2023;4:101233. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101233.","journal-title":"Cell Rep Med"},{"key":"1247_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121:257\u201363. https:\/\/doi.org\/10.1038\/s41416-019-0508-4.","journal-title":"Br J Cancer"},{"key":"1247_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"K-H Jun","year":"2014","unstructured":"Jun K-H, Kim J-H, Jung J-H, Choi H-J, Chin H-M. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int J Surg. 2014;12:156\u201362. https:\/\/doi.org\/10.1016\/j.ijsu.2013.11.022.","journal-title":"Int J Surg"},{"key":"1247_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23:283. https:\/\/doi.org\/10.1186\/s12876-023-02924-y.","journal-title":"BMC Gastroenterol"},{"key":"1247_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cncy.22688","volume":"131","author":"J Dai","year":"2023","unstructured":"Dai J, Zheng H, Jin J, Cheng Y, Xu H. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: a comparative study with tissue specimens. Cancer Cytopathol. 2023;131:365\u201372. https:\/\/doi.org\/10.1002\/cncy.22688.","journal-title":"Cancer Cytopathol"},{"key":"1247_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-26388-0","volume":"15","author":"Y Miki","year":"2025","unstructured":"Miki Y, Yoshii M, Miyauchi R, Bito T, Kuroda K, Kasashima H, et al. Prognostic significance of Claudin18.2 expression in patients with gastric cancer. Sci Rep. 2025;15:39072. https:\/\/doi.org\/10.1038\/s41598-025-26388-0.","journal-title":"Sci Rep"},{"key":"1247_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells14211672","volume":"14","author":"VCE Njoku","year":"2025","unstructured":"Njoku VCE, Lee Y, Ramesh J, Kubatka P, B\u00fcsselberg D. Precision antibody therapy in gastric and gastroesophageal cancer: targeting FGFR2b, CLDN18.2, and VEGFR2. Cells. 2025;14:1672. https:\/\/doi.org\/10.3390\/cells14211672.","journal-title":"Cells"},{"key":"1247_CR34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30:1487\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdz199.","journal-title":"Ann Oncol"},{"key":"1247_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"key":"1247_CR36","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee K-W, Shitara K, Metges J-P, Lonardi S, Ilson DH, et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2023;29:3882\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0204.","journal-title":"Clin Cancer Res"},{"key":"1247_CR37","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41591-026-04306-9","volume":"32","author":"K Shitara","year":"2026","unstructured":"Shitara K, Shoji H, Fazio N, Lonardi S, Lee K-W, Bai L-Y, et al. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026;32:2182\u201390. https:\/\/doi.org\/10.1038\/s41591-026-04306-9.","journal-title":"Nat Med"},{"issue":"8","key":"1247_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103663","volume":"9","author":"F Lordick","year":"2024","unstructured":"Lordick F, Cutsem EV, Shitara K, Xu R-H, Ajani JA, Shah MA, et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024;9(8):103663. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103663.","journal-title":"ESMO Open"},{"key":"1247_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06406-4","volume":"152","author":"K Shimozaki","year":"2025","unstructured":"Shimozaki K, Ooki A, Fukuoka S, Osumi H, Yoshikawa K, Yoshino K, et al. Safety and efficacy of zolbetuximab plus chemotherapy for Claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience. J Cancer Res Clin Oncol. 2025;152:16. https:\/\/doi.org\/10.1007\/s00432-025-06406-4.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1247_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100131","volume":"7","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Pazo-Cid RA, Lonardi S, Swanson L, Arango MJ, Enzinger P, et al. Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND\/UCLA modified Delphi panel study. ESMO Gastrointest Oncol. 2025;7:100131. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100131.","journal-title":"ESMO Gastrointest Oncol."},{"key":"1247_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65148-6","volume":"16","author":"EJ Carstens","year":"2025","unstructured":"Carstens EJ, Takahashi K, Sakamoto N, De Vizio M, Morgado M, Nikkhoi SK, et al. Modeling and addressing on-target\/off-tumor toxicity of Claudin 18.2 targeted immunotherapies. Nat Commun. 2025;16:9651. https:\/\/doi.org\/10.1038\/s41467-025-65148-6.","journal-title":"Nat Commun"},{"key":"1247_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/jjco\/hyaf055","volume":"55","author":"Y Yanagimoto","year":"2025","unstructured":"Yanagimoto Y, Yamamoto K, Hara K, Masuike Y, Ushimaru Y, Kitamura M, et al. Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer. Jpn J Clin Oncol. 2025;55:825\u201331. https:\/\/doi.org\/10.1093\/jjco\/hyaf055.","journal-title":"Jpn J Clin Oncol"},{"key":"1247_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105805","volume":"10","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Owaki Y, Nakayama I, Sakamoto N, Ishizaka M, Kadota T, et al. Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ESMO Open. 2025;10:105805. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105805.","journal-title":"ESMO Open"},{"key":"1247_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1644263","volume":"15","author":"Y Mitsui","year":"2025","unstructured":"Mitsui Y, Sato Y, Shinomiya R, Sumida S, Fujimoto S, Okada A, et al. Case report: zolbetuximab-induced gastritis with protein-losing gastroenteropathy and hypogammaglobulinemia: a case implicating IgA vasculitis. Front Oncol. 2025;15:1644263. https:\/\/doi.org\/10.3389\/fonc.2025.1644263.","journal-title":"Front Oncol"},{"key":"1247_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"D-Y Ruan","year":"2025","unstructured":"Ruan D-Y, Liu F-R, Wei X-L, Luo S-X, Zhuang Z-X, Wang Z-N, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"key":"1247_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS462","volume":"44","author":"K Shitara","year":"2026","unstructured":"Shitara K, Janjigian YY, Elimova E, Zhang J, Chen M-H, Smyth EC, et al. CLARITY-Gastric 01: a randomized phase 3 study of sonesitatug vedotin (sone ve), a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC\/GEJC). J Clin Oncol. 2026;44:TPS462. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.TPS462.","journal-title":"J Clin Oncol"},{"key":"1247_CR47","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","volume":"31","author":"G Ku","year":"2025","unstructured":"Ku G, Shen L, Dayyani F, Kratz J, Liang X, Liu F, et al. A first-in-human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors. Clin Cancer Res. 2025;31:4944\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4280.","journal-title":"Clin Cancer Res"},{"key":"1247_CR48","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"key":"1247_CR49","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8.","journal-title":"Lancet"},{"key":"1247_CR50","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0.","journal-title":"Lancet"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01247-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:18Z","timestamp":1790916678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01247-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01247-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No external funding was used in the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robin Grellet, Paul Rat, Olivier Facy, and Nicolas Santucci have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robin Grellet: Conceptualization, Investigation, Writing \u2013 original draft, Writing \u2013 review and editing. Paul Rat: Investigation, Writing \u2013 original draft, Writing \u2013 review and editing, Supervision. Olivier Facy: Investigation, Writing \u2013 original draft, Writing \u2013 review and editing, Supervision. Nicolas Santucci: Investigation, Writing \u2013 original draft, Writing \u2013 review and editing, Supervision. All authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Authors Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}